First Trust Dorsey Wright Dynamic Focus 5 ETF FVC
Set alert
43.26 USD -0.36 -0.84%
At close · Oct 30
43.26 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
42.93 Day range 43.60
33.81 52-week range 43.88
- YTD
- +18.93%
- 1 year
- +20.29%
- Open
- 43.60
- Prev close
- 43.62
- Mkt cap
- 113.76M
- Vol
- 27.78K
- Avg vol
- 3.05K
- EPS
- 1.97
- P/E
- 21.95
- Div yield
- 0.00%
More statistics
- Low
- 42.93
- High
- 43.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 37.10
- 200-d avg
- 35.09
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 22.68
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 37.10
- 200-day average
- 35.09
About First Trust Dorsey Wright Dynamic Focus 5 ETF
The fund will normally invest at least 80% of its net assets in the ETFs that comprise the index. The index is designed to provide targeted exposure to the five First Trust sector and industry-based ETFs that the index determines offer the greatest potential to outperform the other First Trust sector and industry-based ETFs and that satisfy certain trading volume and liquidity requirements.
News
- Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
- PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
- Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
- PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Top ETF Stories of May 2022
- 5 ETFs to Tap Hedge Funds' First Inflow in Three Years
- Hedge Fund Assets Hit Record in Q1: 5 ETFs to Tap
- The Reopening Killed The V-Shaped Recovery
- Morgan Stanley Has $33.70 Million Stock Holdings in First Trust Dorsey Wright Dynamic Focus 5 ETF (NASDAQ:FVC)
Your note
Sign in to keep a note on FVC — it syncs with the Stock Master app.